However, data from EMPA‐HEART (Effect of Empagliflozin on Left Ventricular Mass in Patients With Type 2 Diabetes Mellitus and Coronary Artery Disease), which demonstrated significant improvements in LVM following SGLT2 inhibition, found that these changes were independent of systemic blood pressure changes.28 Here, SLC5A2 is linked to coronary artery disorder.